PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT INTELLIPHARMACEUTICS INTERNATIONAL INC.Intellipharmaceutics International Inc. • March 20th, 2018 • Pharmaceutical preparations
THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the six month anniversary of the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [____]1 (the “Termination Date) but not thereafter, to subscribe for and purchase from Intellipharmaceutics International Inc., a company organized under the laws of Canada (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is one of the Common Stock Purchase Warrants (the "Warrants") issued pursuant to that certain Engagement Letter, dated as of March 18, 2018, by and between
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 20th, 2018 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 19, 2018, between Intellipharmaceutics International Inc., a company organized under the laws of Canada (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 31st, 2011 • Intellipharmaceutics International Inc. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of January ___, 2011, between Intellipharmaceutics International Inc., a Canadian corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
INTELLIPHARMACEUTICS INTERNATIONAL INC. UNDERWRITING AGREEMENTUnderwriting Agreement • October 12th, 2018 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • New York
The undersigned, Intellipharmaceutics International Inc., a corporation formed under the laws of Canada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Intellipharmaceutics International Inc. (the “Company”)), hereby confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (hereinafter referred to as “you” (including its correlatives) or the “Underwriter”) as follows:
COMMON SHARE PURCHASE WARRANT INTELLIPHARMACEUTICS INTERNATIONAL Inc.Intellipharmaceutics International Inc. • May 27th, 2016 • Pharmaceutical preparations • New York
THIS COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _______________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on June ___, 2021 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Intellipharmaceutics International Inc., a Canadian corporation (the “Company”), up to ______ common shares of the Company, no par value (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is one of a series of warrants (collectively, the “Warrants”) that were originally issued pursuant to that certain Underwriting Agreement, dated as of May [•], 2016, between the Com
UNDERWRITER COMMON SHARE PURCHASE WARRANT INTELLIPHARMACEUTICS INTERNATIONAL INC.Intellipharmaceutics International Inc. • October 12th, 2018 • Pharmaceutical preparations • New York
THIS UNDERWRITER COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ______________1 (the “Termination Date”) but in no event after five (5) years following the effective date offering pursuant to which this Warrant is being issue in accordance with FINRA Rule 5110(f)(2)(G)(i), to subscribe for and purchase from Intellipharmaceutics International Inc., a Canadian corporation (the “Company”), up to ______ Common Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to the Registration Statement which Registration Sta
PRE-FUNDED COMMON SHARE PURCHASE WARRANT INTELLIPHARMACEUTICS INTERNATIONAL INC.Intellipharmaceutics International Inc. • October 12th, 2018 • Pharmaceutical preparations • New York
THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”), to subscribe for and purchase from Intellipharmaceutics International Inc., a Canadian corporation (the “Company”), up to ______ Common Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to the Registration Statement which Registration Statement also registers the Warrant Shares issuable upon exercise of this Warrant.
STRICTLY CONFIDENTIAL Intellipharmaceutics International Inc.Letter Agreement • March 4th, 2019 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 31st, 2011 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of January __, 2011, between Intellipharmaceutics International Inc., a Canadian corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
COMMON SHARE PURCHASE WARRANT INTELLIPHARMACEUTICS INTERNATIONAL INC.Common Share Purchase Warrant • October 12th, 2018 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • New York
THIS COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ______________1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Intellipharmaceutics International Inc., a Canadian corporation (the “Company”), up to ______ Common Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to the Registration Statement which Registration Statement also registers the Warrant Shares issuable upon exercise of this Warrant.
STRICTLY CONFIDENTIAL Intellipharmaceutics International Inc.Letter Agreement • March 16th, 2018 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • New York
INTELLIPHARMACEUTICS INTERNATIONAL INC. 1,818,182 Common Shares PLACEMENT AGENT AGREEMENTIntellipharmaceutics International Inc. • March 9th, 2012 • Pharmaceutical preparations • New York
ESCROW AGREEMENTEscrow Agreement • June 1st, 2010 • IntelliPharmaCeutics International Inc. • Pharmaceutical preparations • Ontario
This Agreement is being entered into by the Parties under the Toronto Stock Exchange Escrow Policy Statement (the “Policy”) in connection with the listing on the Toronto Stock Exchange (the “TSX”) of the common shares of the Issuer.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. [*****] indicates the redacted confidential portions of this...License and Commercial Supply Agreement • March 30th, 2020 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • New Jersey
THIS LICENSE AND COMMERCIAL SUPPLY AGREEMENT (“Agreement”) is made and entered into as of September 2, 2019 (“Effective Date”) by and among Tris Pharma, Inc, with offices at 2033 US Rt 130, Monmouth Jn, NJ 08852 (“Tris”) and Intellipharmaceutics Corp, with offices at 30 Worcester Road, Toronto, ON M9W 5X2, Canada (“IPC”), with respect to the manufacture, supply, sales, licensing and distribution of the generic pharmaceutical Product set forth below. Tris and IPC are sometimes hereafter referred to individually as a “Party” and collectively as the “Parties.”
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • April 14th, 2014 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • New York
This License and Commercialization Agreement (the “Agreement”) is hereby entered into and effective as of November 21, 2005 (the “Effective Date”) by and between IntelliPharmaCeutics Corp. ("IPC"), a Nova Scotia corporation, with offices located at 30 Worcester Road, Toronto, Ontario, Canada and Par Pharmaceutical, Inc. (“Par”), a Delaware corporation with offices located at 300 Tice Boulevard, Woodcliff Lake, New Jersey 07677, USA. IPC and Par shall each be defined as a “Party” and together as the “Parties” under this Agreement.
ContractIndenture of Lease • March 21st, 2016 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • Ontario
INDENTURE OF LEASE made as of the 1 st day of December, 2015 between FINLEY W. McLACHLAN PROPERTIES INC. and DUFFERIN LUMBER AND SUPPLY COMPANY LIMITED, both Ontario corporations (collectively the “Landlord”), and INTELLIPHARMACEUTICS CORP., a Nova Scotia corporation (the “Tenant”).
Fifth Amendment to Lease AgreementFifth Amendment to Lease Agreement • February 27th, 2015 • Intellipharmaceutics International Inc. • Pharmaceutical preparations
This Fifth Amendment to Lease Agreement ("Amendment”) is made and entered into as of the 28th day of November 2014, by and between Finley W. McLachlan Properties Inc., (the "Landlord") and IntelliPharmaCeutics Corp., (the "Tenant”)
INTELLIPHARMACEUTICS INTERNATIONAL INC. 1,815,000 Units Each Consisting of One Common Share and One Warrant to Purchase 0.25 of a Common Share PLACEMENT AGENT AGREEMENTIntellipharmaceutics International Inc. • March 19th, 2013 • Pharmaceutical preparations • New York
INTELLIPHARMACEUTICS INTERNATIONAL INC. Common Shares EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • November 27th, 2013 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • New York
INTELLIPHARMACEUTICS INTERNATIONAL INC. UNDERWRITING AGREEMENTUnderwriting Agreement • July 26th, 2013 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • New York
The undersigned, Intellipharmaceutics International Inc., a company incorporated under the laws of Canada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Intellipharmaceutics International Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for whom Maxim Group LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
PROMISSORY NOTE EXTENSIONPromissory Note Extension Agreement • February 6th, 2024 • Intellipharmaceutics International Inc. • Pharmaceutical preparations
LICENSE AND COMMERCIAL SUPPLY AGREEMENTLicense and Commercial Supply Agreement • February 28th, 2017 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • New York
THIS LICENSE AND COMMERCIAL SUPPLY AGREEMENT (“Agreement”) is made and entered into effective this October 11, 2016 (“Effective Date”) by and between Mallinckrodt LLC, a Delaware limited liability company (for and on behalf of its affiliated entities) (“Mallinckrodt”) and Intellipharmaceutics Corp., a company organized under the laws of Canada (for and on behalf of its affiliated entities) (“Intellipharmaceutics”).
ContractIsa Odidi and Amina Odidi • June 1st, 2010 • IntelliPharmaCeutics International Inc. • Pharmaceutical preparations • Delaware
TARO PHARMACEUTICALS INC. -and- INTELLIPHARMACEUTICS, CORP. LICENCE AND SUPPLY AGREEMENT Desvenlafaxine Extended-Release Tablets (50 mg and 100 mg desvenlafaxine succinate) FOR SALE IN CANADA LICENSE AND SUPPLY AGREEMENTLicence and Supply Agreement • February 6th, 2024 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • Ontario
THIS AGREEMENT, made as of July 29, 2022 (the “Effective Date”) between Taro Pharmaceuticals Inc., having its offices at 130 East Road, Brampton, Ontario, Canada, L6T 1C1 (“Taro”), and Intellipharmaceutics, Corp., having its offices at 30 Worcester Road, Toronto, Ontario, Canada M9W 5X2 (“IPC”). Taro and IPC are herein sometimes referred to individually as a “Party” and collectively as the “Parties”.
ARRANGEMENT AGREEMENT Made as of August 14, 2009 Between VASOGEN INC. (“Vasogen”) and INTELLIPHARMACEUTICS CORP. (“IPC Opco”) and INTELLIPHARMACEUTICS LTD. (“IPC US”)Arrangement Agreement • June 1st, 2010 • IntelliPharmaCeutics International Inc. • Pharmaceutical preparations • Ontario
INTELLIPHARMACEUTICS CORP., an unlimited liability corporation incorporated under the laws of the Province of Nova Scotia
LEASE DEFAULT AGREEMENTLease Default Agreement • March 31st, 2021 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • Ontario
